Full-Time

Director of Regulatory Affairs

Posted on 11/20/2025

McKesson

McKesson

10,001+ employees

Pharmaceuticals and medical supplies distributor.

Compensation Overview

€80.3k - €133.8k/yr

+ Total Rewards + Competitive compensation package + Annual bonus + Long-term incentive

Cork, Ireland

Hybrid

Hybrid work model; occasional international travel.

Category
Legal & Compliance (1)
Requirements
  • Bachelor’s degree or higher in Chemistry, Microbiology, Pharmaceutical Sciences, or a related field.
  • Minimum 12+ years of progressive experience in Regulatory Affairs, Quality Compliance, or related functions within the pharmaceutical, biologics, or medical device industry.
  • Minimum 4+ years in a people leadership role, including responsibility for building teams, driving strategy, and influencing enterprise decisions.
  • Proven track record managing regulatory submissions, labelling, post-market activities, and quality systems oversight.
  • Demonstrated success engaging with global health authorities, leading inspections/audits, and influencing enterprise-level decisions.
  • Experience in private label, distributed product business models, and oversight of third-party manufacturers/service providers is strongly preferred.
  • Integrated Regulatory & Quality Leadership: Deep knowledge of U.S. and global regulatory frameworks (FDA, ICH, DEA, CBP) and GxP-aligned quality systems.
  • Enterprise Leadership: Skilled in leading large, diverse teams, shaping organizational structures, and developing next-generation leaders.
  • Risk & Compliance Strategy: Expertise in inspection readiness, risk management, issue resolution, and regulatory intelligence.
  • Executive Influence: Skilled communicator with the ability to simplify complexity, engage senior stakeholders, and represent the enterprise to regulators.
  • Digital Fluency: Proficiency with regulatory and quality platforms and digital tools to drive transformation.
  • Change Leadership: Ability to lead through ambiguity, balancing compliance rigor with agility and business continuity.
  • Business Acumen: Strong ability to align compliance objectives with commercial priorities to enable sustainable growth.
  • Risk & Response Management: Calm, strategic, and decisive under pressure; experienced in managing regulatory crises, recalls, or escalations in collaboration with Legal, Quality, and executive stakeholders.
  • Advanced Proficiency in Regulatory and Quality Management applications, supporting document control, workflow automation, and compliance assurance.
  • Highly proficient in using SharePoint, and integrated platforms to facilitate global team coordination and secure document collaboration.
  • Proficient in Smartsheet, with capability in building dynamic project dashboards, managing cross-functional timelines, and driving visibility across regulatory initiatives
  • Adept at leveraging digital platforms to streamline regulatory workflows, improve visibility, and support compliance with industry best practices.
Responsibilities
  • Define and execute the integrated Regulatory Affairs and Quality Compliance strategy, aligning with FDA, ICH, DEA, CBP, and international frameworks to ensure compliant growth and sustained market access.
  • Advise executive leadership on regulatory and quality compliance posture, operational risk, and business impact, shaping internal policy and influencing enterprise direction.
  • Lead, develop, and inspire a high-performing integrated Regulatory Affairs and Quality Compliance leadership team, fostering a culture of transparency, accountability, and regulatory and quality excellence.
  • Oversee organizational design, succession planning, and capability development to build resilient, future-ready talent pipelines.
  • Manage headcount planning, resource allocation, and budget alignment to support enterprise priorities.
  • Deliver enterprise visibility through advanced dashboards, risk-based reporting, and data-driven insights to inform senior decision-making.
  • Represent Regulatory Affairs and Quality Compliance in enterprise governance forums, ensuring regulatory and quality perspectives are embedded in strategic planning and risk management.
  • Provide end-to-end strategic oversight of all regulatory submissions and product labelling initiatives for both new and mature products, ensuring alignment with global registration requirements and ongoing compliance standards.
  • Lead post-market programs, including adverse event monitoring, medical information, complaints handling, and Risk Evaluation and Mitigation Strategies (REMS). Ensure readiness for recalls and timely regulatory reporting.
  • Oversee the development, implementation, and continuous improvement of the Quality Management System to support compliance with applicable regulatory and quality standards across all product categories.
  • Oversee compliance with Controlled Substance Monitoring Programs (CSMP) and DSCSA suspect/illegitimate product investigations.
  • Act as a principal regulatory representative during inspections, audits, and regulatory engagements, ensuring organizational readiness and providing authoritative guidance.
  • Represent the company with regulatory agencies and industry bodies, safeguarding organizational credibility and influencing evolving policy landscapes.
  • Ensure robust compliance policies and procedures reflect emerging regulatory requirements, global distribution models, and evolving business needs.
  • Partner cross-functionally with Quality, Supply Chain, Legal, Commercial, and Compliance functions to integrate Regulatory Affairs & Quality Compliance considerations into business processes
  • Drive enterprise-wide signal detection and root cause analytics to proactively identify and mitigate product risks.
  • Ensure agreements, auditing programs, and monitoring mechanisms are in place for all third-party partners and service providers.
  • Lead enterprise responses to regulatory escalations, market actions, or compliance crises, ensuring timely, coordinated, and compliant resolution
  • Define and track regulatory performance metrics (KPIs), driving continuous improvement, right-first-time execution, and alignment with enterprise compliance and operational goals
Desired Qualifications
  • Experience in private label, distributed product business models, and oversight of third-party manufacturers/service providers is strongly preferred.

McKesson is a global healthcare distributor and services provider. It buys pharmaceuticals and medical products from manufacturers and distributes them to pharmacies, hospitals, and other healthcare facilities, acting as an intermediary in the supply chain. Its core work includes logistics and supply chain management, ensuring medicines and medical supplies reach customers on time and safely. McKesson also offers technology solutions to help healthcare providers manage operations and procurement. Compared with competitors, it leverages a very large-scale network and integrated services—combining distribution, logistics, and technology—across providers, pharmacies, and manufacturers. The company aims to support the healthcare system by keeping essential medical supplies available and helping healthcare facilities run more efficiently, ultimately improving patient care.

Company Size

10,001+

Company Stage

IPO

Headquarters

Irving, Texas

Founded

1833

Simplify Jobs

Simplify's Take

What believers are saying

  • Specialty-drug and oncology volumes supported Q4 fiscal 2026 U.S. Pharmaceutical growth.[3]
  • The planned Medical-Surgical IPO can unlock value and sharpen focus on core distribution.[1]
  • A $5 billion revolving credit facility gives room for acquisitions and technology investment.[1]

What critics are saying

  • Brand-drug price declines and GLP-1 volume weakness already cut first-quarter revenue.[1]
  • Biosimilar execution risks threaten specialty-margin expansion if launches slip or uptake disappoints.[1]
  • Regulatory and buyer pressure compresses distribution spreads in McKesson's lowest-margin core business.[1][2]

What makes McKesson unique

  • North American Pharmaceutical, Oncology, Medical-Surgical, and Prescription Technology units diversify revenue.[3]
  • McKesson distributes pharmaceuticals and medical supplies to pharmacies, hospitals, and health systems.[4][5]
  • Its scale spans a third of North American pharmaceutical products and 24% wholesaling share.[1][2]

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at McKesson who can refer or advise you

Benefits

Performance Bonus

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Cadillac News
Apr 7th, 2026
Latent raises $80M to close the gap between diagnosis and treatment.

Latent raises $80M to close the gap between diagnosis and treatment. * Business Wire * 2 hrs ago SAN FRANCISCO-(BUSINESS WIRE)-Apr 7, 2026- Latent, the clinical-AI company accelerating access to life-saving medications, has raised an $80M Series A co-led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator. Today, Latent works with 50% of the top 20 U.S. health systems. Sri Somasundaram (left), Rish Jain (right), Co-CEOs and Co-Founders of Latent Modern medicine has advanced faster than the systems that deliver it. Today in the U.S., a patient and their doctor will sit together, look at a diagnosis, and decide on a treatment. In 42% of critical cases, that life-saving medication will be delayed or denied and may not reach the patient. This is not because the medicine doesn't exist or the doctor made the wrong call, but because every therapy a patient receives must pass through a gauntlet of clinical documentation, payer rules, and pharmacy coordination. Discover more Coupon publications Local sports coverage That gauntlet is currently held together by manual labor: clinicians toggling between systems, pharmacy teams re-keying information, staff navigating phone trees to prove what a patient's own chart already shows. The work is clinical in nature; it involves interpreting labs, applying treatment criteria, matching diagnoses to coverage rules. It is among the highest-stakes knowledge work in healthcare, and it is done almost entirely by hand. For the first time, AI makes it possible to close the distance between a therapeutic decision and a patient receiving therapy. Latent is building the Clinical Reasoning Engine. The engine performs clinical knowledge work by reasoning through patient data, interpreting drug criteria, extracting key evidence, and orchestrating workflows across stakeholders. By connecting the EHR, payer guidelines, pharmacy operations, and patient engagement with a single engine, Latent replaces the fragmented, manual work that sits between a doctor's order and a patient's treatment with AI agents that perform it instantly and at scale, all to help providers move a patient from decision to therapy the same day. Latent started with prior authorization, the most acute expression of the problem: high provider burnout, high stakes where patients can abandon therapy, and complex clinical decision-making. Meeting that challenge required mastering drug criteria and reasoning over medical records. Having demonstrated its ability to deliver on one of healthcare's hardest problems, the company is now expanding its engine across every process where clinical knowledge must be translated into action. Today, over2 million patientsannually are accessing life-changing medications faster because of Latent. Over the past year, the company has scaled from 4 to more than 45 health system partners and now serves 50% of the top 20 U.S. health systems - including Yale New Haven Health, Ochsner Health, MetroHealth, UCI, Vanderbilt Health, Mount Sinai Health System, Henry Ford Health System, UCSF Health, and UCLA Health. Across nearly every specialty and therapeutic area, Latent is reducing denials by more than 30% and enabling clinicians to serve twice as many patients. Discover more Senior lifestyle products Crosswords and contests Crossword puzzle books Looking to the future, Latent's Clinical Reasoning Engine will be applied proactively to identify when patients should begin therapy and ensure they stay on it. Every day, treatments that could help patients are delayed, denied or not identified. The company is building the infrastructure for the intersection of clinicians, patients, and payers, powering the knowledge work that determines what care patients actually receive. With the Series A financing, the company will expand its health system footprint, deepen the platform connecting hospitals, payers, pharmacies, and patients, continue investing in the reliability and trust required to operate in healthcare, and scale the team. Latent is a home for exceptional talent who believe responsibility doesn't end at diagnosis, it extends to making sure patients actually receive care. About Latent Health Latent Health is the leading AI platform for medication access. The company brings clinical intelligence directly into the patient record, helping care teams move patients from clinical decision to therapy faster and more reliably. Latent is helping more than 2 million patients annually and is trusted by more than 45 of the nation's leading health systems, including Yale New Haven Health, Ochsner Health, MetroHealth, UCI, Vanderbilt Health, Mount Sinai Health System, Henry Ford Health System, UCSF Health, and UCLA Health. Founded by Sriram Somasundaram and Rishabh Jain, Latent has raised $80M in total funding from Transformation Capital, Spark Capital, McKesson Ventures, Conviction, General Catalyst, Y Combinator, and others. To learn more, visit latenthealth.com, and see open roles at latenthealth.com/careers. KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SOFTWARE PHARMACEUTICAL HEALTH ARTIFICIAL INTELLIGENCE DATA MANAGEMENT HOSPITALS HEALTH TECHNOLOGY TECHNOLOGY PUB: 04/07/2026 04:23 PM/DISC: 04/07/2026 04:23 PM From the Web Powered by

Yahoo Finance
Apr 7th, 2026
BofA cuts McKesson price target to $1,000 on GLP-1 pricing pressure concerns

Bank of America analyst Allen Lutz has lowered McKesson Corporation's price target to $1,000 from $1,040 whilst maintaining a Buy rating. The analyst cited concerns that rapidly declining cash-pay GLP-1 prices are shifting prescriptions away from insurance coverage. BofA warned that strong growth in cash-pay scripts for Wegovy and Zepbound could pressure McKesson's fiscal year 2027 EBIT guidance in its Prescription Technology Solutions segment, potentially falling below market expectations. Separately, McKesson announced in March that CFO Britt Vitalone will retire after 20 years with the company. Kenny Cheung will succeed him as executive vice president and CFO on 29 May 2026. Vitalone will remain as a strategic adviser during the transition.

TipRanks
Apr 7th, 2026
McKesson Secures New $2 Billion Senior Credit Facilities - TipRanks.com

The latest update is out from McKesson ( ($MCK) ). On April 1, 2026, McKesson subsidiaries, including McKesson Medical-Surgical Top Holdings, entered into a new sen...

AInvest
Apr 2nd, 2026
MedMira reports Q2 FY2025 results, signs distribution agreement with McKesson, and publishes clinical trial results.

MedMira reports Q2 FY2025 results, signs distribution agreement with McKesson, and publishes clinical trial results. Wednesday, Apr 1, 2026 10:11 pm ET 1min read MedMira reported Q2 FY2025 financial results with revenue of $24,503, a gross profit of $18,132, and operating expenses of $423,180. The company signed a distribution agreement with McKesson, expanded its product offering, and published clinical trial results for its Multiplo Complete Syphilis test. Clinical trials for the Multiplo TP/HIV self-test have progressed, and the company is working on its MiROQ technology. Ask Aime: How does MedMira's Q2 FY2025 financial performance align with its long-term growth prospects? Aime insights. What powerful indicators do day traders use? How do operating cash flows compare among top e-commerce giants over the decade? How is the S&P 500 performing today, and could you explain the reasons behind it? Among the Magnificent 7, which stock offers the best value to buy now?

Yahoo Finance
Mar 25th, 2026
McKesson beats Q4 revenue estimates with $106B as healthcare providers deliver mixed earnings

McKesson reported Q4 revenues of $106.2 billion, up 11.4% year on year, meeting analysts' expectations. The healthcare services company delivered mixed results, narrowly beating full-year earnings per share guidance whilst revenue matched estimates. The 40 healthcare providers and services stocks tracked reported a mixed Q4 overall. As a group, revenues beat consensus estimates by 1.2%, whilst next quarter's guidance was in line. Share prices have struggled, declining 5.8% on average since earnings. RadNet emerged as the quarter's top performer, reporting revenues of $547.7 million, up 14.8% year on year and beating expectations by 5.8%. Despite strong results, RadNet's stock fell 14.2% post-earnings to $59.91, whilst McKesson gained 7.8% to $886.50.

INACTIVE